Detail akcie Atara Biother Rg online

Business Summary: Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Atara Biotherapeutics Inc revenues increased 24% to $119.2M. Net income totaled $36.1M vs. loss of $72.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Developing and Commercializing therapeautics segment income totaling $38.4M vs. loss of $71.2M.